CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
42
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. CytoMed Therapeutics Ltd market cap is $8.93M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. CytoMed Therapeutics Ltd 52 week high is $2.12 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. CytoMed Therapeutics Ltd 52 week low is $0.6801 as of November 22, 2026.
CytoMed Therapeutics Ltd stock price today is $0.755.
CytoMed Therapeutics Ltd stock price yesterday was $0.773.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. CytoMed Therapeutics Ltd's P/E ratio is -3.27.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. CytoMed Therapeutics Ltd P/B ratio is 2.3438.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. CytoMed Therapeutics Ltd 50-day moving average is $0.8842.